Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. (GALT) reports a corporate governance event dated March 12, 2026. The company is a Nevada corporation with its principal executive office in Norcross, GA, and its common stock trades on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the appointment of Dr. Henry Brem to the Board of Directors, effective March 12, 2026. There are no reported changes to financial performance or capital structure in this document.
Management Commentary and Risks
- Appointment Details: Dr. Brem was appointed without any arrangement or understanding with other persons and will not serve on any board committees at the time of appointment.
- Compensation: Dr. Brem will be compensated in accordance with the Company's standard non-employee director compensation program as described in the most recent proxy statement.
- Qualifications: The Board cites Dr. Brem's extensive experience as an internationally recognized neurosurgeon-scientist, former Director of the Department of Neurosurgery at Johns Hopkins (2000-2025), and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.
- Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing.
Investor Verification Checklist
- Verify the specific terms of the standard non-employee director compensation program referenced in the Company's most recent proxy statement.
- Confirm Dr. Brem's current committee assignments and any future changes to his board role.
- Review the press release dated March 17, 2026 (Exhibit 99.1) for additional context on the appointment.